New drug ATH-097 enters first human safety trial
NCT ID NCT07640269
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial will test the safety and tolerability of a single dose of ATH-097 in 44 healthy adults aged 18 to 55. Participants will be randomly assigned to receive either ATH-097 or a placebo, and researchers will monitor for side effects and measure how the drug is processed in the body. The study is not yet recruiting and is designed to gather initial safety data before any future studies in patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ATH-097
What could go wrong
This is an early Phase 1 study in healthy volunteers, so it only tests safety and how the drug moves through the body. It does not test if ATH-097 works for any disease, and many early-stage drugs fail to show benefit or have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THIS IS A PHASE I STUDY CONDUCTED IN HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nucleus Network Pty Ltd.
Melbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••